Drug Search Results
More Filters [+]

IMO-2055

Alternative Names: imo-2055, imo2055, imo 2055
Latest Update: 2018-06-12
Latest Update Note: Clinical Trial Update

Product Description

a TLR9 agonist for cancer treatment being developed by Merck KGaA, Darmstadt, Germany, under its collaboration with Idera.Ê (Sourced from: https://ir.iderapharma.com/news-releases/news-release-details/idera-pharmaceuticals-provides-update-imo-2055-clinical)

Mechanisms of Action: TLR9 Agonist

Novel Mechanism: Yes

Modality: Nucleic Acid

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: EMD Serono
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IMO-2055

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Head and Neck Cancer|Squamous Cell Carcinoma|Renal Cell Carcinoma

Phase 1: Non-Small-Cell Lung Cancer|Colorectal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

R/M SCCHN

P2

Completed

Squamous Cell Carcinoma|Head and Neck Cancer

2012-01-01

IMO-2055-210

P1

Terminated

Colorectal Cancer

2011-04-01

EMR 200068-200

P1

Completed

Non-Small-Cell Lung Cancer

2010-10-01

NCT00729053

P2

Completed

Renal Cell Carcinoma

2008-04-01

Recent News Events

Date

Type

Title